Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis-Reference-Cited by-同舟云学术

Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis

Published:2007-02-16 Issue:5 Volume:13 Page:567-577
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Farrell Rachel A¹,Giovannoni Gavin²

Affiliation:

1. Department of Neuroimmunology, Institute of Neurology, London, UK

2. Department of Neuroimmunology, Institute of Neurology, London, UK,

Abstract

Interferon Beta is well established as a first line agent to treat relapsing remitting Multiple Sclerosis. It frequently induces the formation of neutralising anti-Interferon Beta Antibodies (Nabs) which may abrogate the clinical efficacy of the drug. Numerous studies have shown a loss of bioactivity of the drug in the presence of Nabs. The focus has shifted to reliable quantification of Nabs and their appropriate incorporation into clinical practice. Here we review the development and persistence of Nabs, the effect on Interferon beta bioactivity, clinical and para-clinical autocome measures in trials, Nab assays and discuss management strategies to optimise the use of Interferon beta in relapsing remitting MS. Multiple Sclerosis 2007; 13: 567-577. http://msj.sagepub.com

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458506073522

Reference69 articles.

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial

2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial

3. PRISMS-4: Long-term efficacy of interferon- -1a in relapsing MS

4. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

5. Evidence of interferon β-1a dose response in relapsing-remitting MS

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis;CNS Drugs;2022-05-19

2. Be aware that the benefits of biological drugs in multiple sclerosis may be offset by their capacity to cause immunological complications;Drugs & Therapy Perspectives;2019-11-25

3. Different Interferon Beta Preparations Induce the Same Qualitative Immune Response in Human Skin;Journal of Interferon & Cytokine Research;2019-05

4. Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis;Drug Safety;2019-03-04

5. A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-;Current Drug Metabolism;2018-12-27